These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2111751)

  • 1. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.
    Hartman NR; Yarchoan R; Pluda JM; Thomas RV; Marczyk KS; Broder S; Johns DG
    Clin Pharmacol Ther; 1990 May; 47(5):647-54. PubMed ID: 2111751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.
    Knupp CA; Shyu WC; Dolin R; Valentine FT; McLaren C; Martin RR; Pittman KA; Barbhaiya RH
    Clin Pharmacol Ther; 1991 May; 49(5):523-35. PubMed ID: 1903100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of altered metabolism in dideoxynucleoside pharmacokinetics. Studies of 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats.
    Singhal D; Morgan ME; Anderson BD
    Drug Metab Dispos; 1996 Oct; 24(10):1155-61. PubMed ID: 8894519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in mice.
    el Dareer SM; Tillery KF; Kalin JR; Hill DL
    Invest New Drugs; 1989 Jul; 7(2-3):139-46. PubMed ID: 2507472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of brain tissue localized purine metabolizing enzymes in the central nervous system delivery of anti-HIV agents 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats.
    Singhal D; Morgan ME; Anderson BD
    Pharm Res; 1997 Jun; 14(6):786-92. PubMed ID: 9210198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.
    Hartman NR; Yarchoan R; Pluda JM; Thomas RV; Wyvill KM; Flora KP; Broder S; Johns DG
    Clin Pharmacol Ther; 1991 Sep; 50(3):278-85. PubMed ID: 1914362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex.
    Pai SM; Shukla UA; Grasela TH; Knupp CA; Dolin R; Valentine FT; McLaren C; Liebman HA; Martin RR; Pittman KA
    J Clin Pharmacol; 1992 Mar; 32(3):242-7. PubMed ID: 1564128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2'-beta-fluoro-2',3'-dideoxyadenosine, lodenosine, in rhesus monkeys: plasma and cerebrospinal fluid pharmacokinetics and urinary disposition.
    Roth JS; McCully CM; Balis FM; Poplack DG; Kelley JA
    Drug Metab Dispos; 1999 Oct; 27(10):1128-32. PubMed ID: 10497138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
    Zhou XJ; Squires K; Pan-Zhou XR; Bernhard S; Agrofoglio L; Kirk M; Duchin KL; Sommadossi JP
    J Clin Pharmacol; 1997 Mar; 37(3):201-13. PubMed ID: 9089422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetics of new anti-HIV agents: 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine.
    Russell JW; Klunk LJ
    Biochem Pharmacol; 1989 May; 38(9):1385-8. PubMed ID: 2497744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
    Lambert JS; Seidlin M; Reichman RC; Plank CS; Laverty M; Morse GD; Knupp C; McLaren C; Pettinelli C; Valentine FT
    N Engl J Med; 1990 May; 322(19):1333-40. PubMed ID: 2139173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of 2',3'-dideoxyadenosine in dogs.
    Wientjes MG; Placke ME; Chang MJ; Page JG; Kluwe WM; Tomaszewski JE
    Invest New Drugs; 1991 May; 9(2):159-68. PubMed ID: 1908444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.
    Drusano GL; Yuen GJ; Morse G; Cooley TP; Seidlin M; Lambert JS; Liebman HA; Valentine FT; Dolin R
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1280-3. PubMed ID: 1416828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
    Barry M; Howe JL; Ormesher S; Back DJ; Breckenridge AM; Bergin C; Mulcahy F; Beeching N; Nye F
    Br J Clin Pharmacol; 1994 May; 37(5):421-6. PubMed ID: 8054247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of 2',3'-dideoxyinosine (ddI) in human blood.
    Back DJ; Ormesher S; Tjia JF; Macleod R
    Br J Clin Pharmacol; 1992 Mar; 33(3):319-22. PubMed ID: 1576055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Didanosine.
    Shelton MJ; O'Donnell AM; Morse GD
    Ann Pharmacother; 1992 May; 26(5):660-70. PubMed ID: 1350471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-performance liquid chromatographic analysis of 2'-fluoro-2',3'-dideoxyadenosine and 2'-fluoro-2',3'-dideoxyinosine in dog plasma and urine.
    Campbell DA; Shah VR; Srinivas NR; Shyu WC
    J Pharm Sci; 1996 Aug; 85(8):890-2. PubMed ID: 8863284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of 2',3'-dideoxyinosine and the active metabolite, 2',3'-dideoxyadenosine-5'-triphosphate in human peripheral-blood mononuclear cell by HPLC-MS/MS and the application to cell pharmacokinetics.
    Lan X; Mingdao L; Huilin G; Wei G; Lvjiang H; Yan Z; Gang L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Oct; 1002():337-42. PubMed ID: 26350426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
    Cooley TP; Kunches LM; Saunders CA; Ritter JK; Perkins CJ; McLaren C; McCaffrey RP; Liebman HA
    N Engl J Med; 1990 May; 322(19):1340-5. PubMed ID: 2139174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphatic targeting of anti-HIV nucleosides: distribution of 2',3'-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice.
    Manouilov KK; Xu ZS; Boudinot FD; Schinazi RF; Chu CK
    Antiviral Res; 1997 May; 34(3):91-9. PubMed ID: 9191016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.